Purchase this article with an account.
T. Sawada, M. Kakinoki, O. Sawada, H. Kawamura, M. Ohji; Improvement in Foveal Thickness, Fixation, and Visual Acuity After Intravitreal Bevacizumab or Triamcinolone Acetonide Injection for Branch Retinal Vein. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5388.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the changes in foveal thickness, fixation, and visual acuity (VA) after intravitreal bevacizumab or triamcinolone acetonide injection in patients with branch retinal vein occlusion (BRVO).
We prospectively examined 30 eyes of 30 patients with macular edema associated with BRVO. Thirty patients were treated with an intravitreal injection of either 4 mg of triamcinolone acetonide or 1.25 mg bevacizumab. Ophthalmic examinations were performed at baseline, 1 week, and 1, 3, and 6 months. The logarithm of the minimum angle of resolution (logMAR) VA, foveal thickness, and fixation were measured. Fixation was measured by microperimetry; good fixation was defined as fixation that exceeded 95% within the central 2-degree circle.
The logMAR VA values were 0.66, 0.51, 0.47, 0.52, and 0.44 at baseline, 1 week, and 1, 3, and 6 months, respectively. The foveal thicknesses were 603, 353, 270, 380, and 287µm, respectively; the percentages of patients with good fixation were 53.3%, 63.3%, 80.0%, 70.0%, and 86.7% at each visit, respectively. The logMAR VA values and foveal thicknesses improved significantly after treatment. The foveal thicknesses improved first, followed by improvement of the fixation point and the VA.
The morphologic changes seemed to improve after intravitreal injection for BRVO and this was followed by functional improvement.
Clinical Trial: :
This PDF is available to Subscribers Only